On this page · 5 sections→
Where the EU money came from
Funding by EU programme. Amounts are Cardior Pharmaceuticals GmbH's own share of each project, not the project's full budget.
- Horizon 2020€908k · 1 project
Projects
1 EU-funded project, newest first. Each links to the official record.
- CardioReGenixPartner
CardioReGenix: Development of Next-Generation Gene Therapies for Cardiovascular Disease
Horizon 2020 · 2019–2024 · Project on CORDIS ↗
€908ktheir share
Works most with
Organisations that shared the most EU projects with this one. A good starting list for consortium partners.
- The University of EdinburghUnited Kingdom · 1 shared project
- King'S College LondonUnited Kingdom · 1 shared project
- Vrije Universiteit BrusselBelgium · 1 shared project
- Stichting Amsterdam UmcNetherlands · 1 shared project
- Ita-Suomen YliopistoFinland · 1 shared project
- Christian-Albrechts-Universitaet zu KielGermany · 1 shared project
- Medizinische Hochschule HannoverGermany · 1 shared project
- Asphalion SLSpain · 1 shared project
- Pohjois-Savon Sairaanhoitopiirin KuntayhtymaFinland · 1 shared project
- Batavia Biosciences BVNetherlands · 1 shared project
- A2f Associates LimitedUnited Kingdom · 1 shared project
- Finvector OyFinland · 1 shared project
Fields it works in
Research fields recorded on its Horizon projects.
- cardiology
Is this your organisation?
Claim it with an EUACC listing (€39 once, reviewed by our editors): add what you build, your team and what you are looking for. We pre-fill it from your EU records. Listed companies reach investors through our newsletter and get matched to new EU calls first.
Claim this profile →Source: CORDIS (Horizon Europe, Horizon 2020, FP7) and the EU Funding & Tenders Portal (other EU programmes), matched by the EU registration number (PIC). Past participation does not mean the organisation is open to new partnerships.